High-purity chemical entities and APIs synthesized under rigorous cGMP protocols for global export.
An authoritative analysis of Enzalutamide manufacturing standards, chemical engineering breakthroughs, and global B2B procurement strategies.
Enzalutamide (CAS No: 915087-33-1) represents a critical milestone in targeted oncological pharmacotherapy. As a non-steroidal androgen receptor inhibitor, its synthesis requires stringent control over chemical purity, polymorph stability, and genotoxic impurity profiling. China's chemical manufacturing ecosystem has transformed into the primary global hub for high-grade Enzalutamide API production, supplying global generic drug developers with batch-to-batch consistency and technical documentation (DMF/CEP readiness).
Enzalutamide chemically identified as 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]-2-fluoro-N-methylbenzamide, exerts a potent triple-mechanism androgen receptor blockade. Unlike first-generation antiandrogens, Enzalutamide competitively inhibits androgen binding to receptors, inhibits nuclear translocation of activated receptors, and impairs genomic DNA binding, thereby effectively suppressing prostate cancer cell proliferation even under castration-resistant states.
Export-grade Enzalutamide API demands meticulous control over parameters defining biological effectiveness and safety. Primary CQAs include micronized particle size distribution ($D_{90} < 10\,\mu\text{m}$ for bioavailability enhancement), crystal polymorphism stability (Form I isolation), and strict regulation of residual organosulfur intermediates to prevent off-target toxicity in solid oral dosage drug formulations.
Analyzing therapeutic expansion, patent transition curves, and international procurement standards for Enzalutamide.
Initially approved for metastatic castration-resistant prostate cancer (mCRPC), Enzalutamide's market has expanded significantly into non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). Global demand for high-purity API continues to surge as clinical guidelines solidify its role in early-stage combination regimens.
As main compound patents near expiration across major international territories between 2026 and 2028, generic pharmaceutical developers are aggressively securing stable API supply chains. Early tech-transfer and analytical evaluation of Chinese Enzalutamide raw materials enable pharmaceutical companies to file early ANDA applications without patent infringement conflicts.
Global procurement teams prioritize vendors offering comprehensive regulatory dossiers, including ICH stability studies, structure elucidation reports (NMR, Mass, IR), and verified non-infringing synthesis routes. China-based manufacturers provide an optimal blend of technical compliance, scale flexibility, and cost competitiveness.
| Test Parameters | Specification Standards | Analytical Method |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual Inspection |
| Identification | Conforms to Structure Standard (IR, 1H-NMR, MS) | Spectroscopic Analysis |
| HPLC Assay Purity | ≥ 99.5% (Dry Basis) | High-Performance Liquid Chromatography |
| Individual Impurity | ≤ 0.05% | Reverse Phase HPLC |
| Total Impurities | ≤ 0.20% | Area Normalization |
| Particle Size Distribution | $D_{50} \le 5\,\mu\text{m}$, $D_{90} \le 10\,\mu\text{m}$ (Customizable) | Laser Diffraction (Malvern) |
| Heavy Metals / Residue on Ignition | ≤ 10 ppm / ≤ 0.1% | USP <231> / USP <281> |
| Residual Solvents | Meets ICH Q3C Guidelines (Acetone, DMF, DCM controlled) | Gas Chromatography (GC-HS) |
Leveraging microreactor technology, automated process analytical technology (PAT), and back-integrated raw material networks.
Modern Chinese API factories utilize continuous microreactor technology for high-hazard steps in Enzalutamide synthesis, such as thiocarbonylation and cyanation. Continuous flow yields superior thermal control, minimizes byproduct formation, and significantly lowers residual hazardous waste.
China's comprehensive chemical infrastructure ensures domestic availability of critical starting materials—such as 4-amino-2-fluoro-N-methylbenzamide and 2-((4-cyano-3-(trifluoromethyl)phenyl)amino)-2-methylpropanenitrile. This vertical independence eliminates supply interruptions during global market disruptions.
Smart manufacturing plants feature integrated Process Analytical Technology (PAT), including inline FTIR and automated particle sizing, ensuring every batch strictly aligns with international cGMP, US FDA, and EDQM quality standards.
Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Documents and Certificates are supported to customers worldwide.
Advanced custom synthetic route design, analytical method validation, and scale-up technical transfer tailored for high-potency APIs and complex molecules.
For those clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide extra customized procurement services with the most superior and comprehensive supply chain sources.
Overcoming bioavailability challenges through advanced amorphous solid dispersion (ASD) and specialized solid oral processing.
Enzalutamide is classified as a BCS Class II/IV drug exhibiting exceptionally low aqueous solubility. Leading global formulators employ Hot-Melt Extrusion (HME) or Spray-Drying Dispersion (SDD) technology using polymers such as HPMCAS or Copovidone to convert crystalline API into a stable amorphous solid dispersion, vastly improving oral absorption and systemic bioavailability.
In addition to API supply, premier Chinese partners provide full FDF development services, including 40mg and 80mg film-coated tablets and liquid-filled softgel capsules. Tech transfer packages include full bioequivalence (BE) study protocols, stability testing packages, and validation dossiers for direct regulatory submission.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
Trusted by pharmaceutical leaders, research institutions, and distribution networks worldwide.
Latest technical updates, peptide API developments, and scientific publications.
Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Originally developed through neuropharmacological research, Selank is a derivative of endogenous peptides...
View Details
As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Thymosin Beta-4 peptide API solutions for biotechnology companies, pharmaceutical research organizations, and commercial drug developers...
View Details
BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its potential biological activities related to tissue repair, gastrointestinal protection, angiogenesis, and inflammatory regulation...
View Details
With continuous development of neuroscience, peptide technology, and life science research, neuroactive peptides have become an important area of scientific investigation. Semax, a synthetic peptide derived from ACTH fragment, has attracted major scientific attention...
View Details
SS-31 API, also known as Elamipretide, MTP-131, Bendavia, and SS31, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane, stabilizing mitochondrial structure and bioenergetics...
View DetailsExpert technical answers regarding Enzalutamide API sourcing, quality documentation, regulatory compliance, and custom synthesis.
Our standard export-grade Enzalutamide API guarantees a minimum HPLC purity of 99.5% on a dry basis, with individual specified impurities controlled below 0.05% and total impurities held under 0.20%, adhering to strict ICH Q3A guidelines.
We supply complete regulatory support packages including Type II Drug Master Files (DMF) for US FDA, ASMF/CEP dossiers for European submissions, Certificate of Analysis (CoA), Stability Data (Accelerated & Long-Term under ICH Q1A), Method Validation Protocols, and Impurity Isolation Reports.
Yes, we offer custom micronization services utilizing fluid energy jet milling. We can tailor particle size specifications (e.g., $D_{90} < 10\,\mu\text{m}$ or $D_{50} < 3\,\mu\text{m}$) to meet the dissolution rate and bioequivalence (BE) requirements of your oral solid dosage or amorphous dispersion formulations.
Through continuous microreactor optimization and catalytic green chemistry, potential alkylating or aromatic amine impurities are controlled at ppm thresholds. Analytical methods such as LC-MS/MS are routinely deployed to verify compliance with ICH M7 guidelines for mutagenic impurities.
For standard commercial API batches, lead times are typically 2 to 4 weeks depending on batch size. Pilot and R&D evaluation quantities start at 100g up to multi-kilogram commercial batches shipped under temperature-controlled logistics.
Explore our full line of synthetic peptides, biochemical reagents, and active pharmaceutical ingredients.
